High Cholesterol – Population, Costs & Treatment

- **Population**
  - 33.5% of US adults have high LDL, less than half are treated
  - Prevalence of Cholesterol Drugs in State Plan –
    - 13.1% in Active/non-Medicare population (12,900)
    - 57.8% in Medicare population (13,047)
  - Familial hypercholesterolemia – unique challenges
    - Intolerance to traditional statins
    - Inability to get to optimal LDL level

- **Costs to State Plan – Cholesterol Drugs Only**
  - $81.34 PMPY in Active/non-Medicare population - $8M annually
  - $483.83 PMPY in Medicare population - $10.9M annually
  - Generic drugs dominate

- **Treatment Guidelines**
  - Evolving treatment guidelines
  - Statins demonstrated improvements in morbidity and mortality
What Are PCSK9 Medications?

- PCSK9 medications are a new class of cholesterol lowering medications (statins)
- Two new drugs in pipeline review pending FDA approval late July and late August
  - Praluent™
  - Repatha™
- Medications are injectable – once or twice per month
Indications for PCSK9 Medications

- Impact will depend on approval protocol by FDA
  - Expected to initially be limited to Familial Hypercholesterolemia indication only
    - Estimated 0.2% of State plan population

- Drug manufacturers are expected to push FDA to expand the clinical indications and volume of patients identified as appropriate for these high cost medications
Financial Impact of PCSK9 Medications

- Cost of PCSK9 estimated at $12,000 annually per patient compared to $600 for traditional statins

- Unmanaged drug utilization would raise prescription costs annually
  - $32.6M for active/non Medicare population
  - $30.8M for Medicare population

- Management of drug utilization will minimize prescription drugs costs annually
  - $4.4M for active/non Medicare population
  - $3.5M for Medicare population
Management of PCSK9 Medications

- Rigorous prior authorization program for any PCSK9 prescribed by provider
- Dispensing limited to specialty providers of Accredo (ESI specialty pharmacy) and Biotek (specialty pharmacy in New Castle, DE)
- Doctors must provide medical documentation and lab tests (commensurate with indications approved)
- Dedicated team of clinicians at ESI to review data submitted
- Home Delivery Option Available to Clients not subject to Any Willing Provider/Pharmacy Access Legislation
Additional Costs for Management of PCSK9 Medications

- ESI will provide the rigorous prior authorization package for PCSK9 drugs at the cost of $0.20 PMPM
- Additional annual administrative fees
  - $236,000 for active/non-Medicare population
  - $54,200 for Medicare population
Follow up

- Will continue to provide updates to SEBC as medications are approved by FDA and more information is available